Literature DB >> 18056772

A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study.

Olivier Valkenburg1, Regine P M Steegers-Theunissen, Huberdina P M Smedts, Geesje M Dallinga-Thie, Bart C J M Fauser, Egbertine H Westerveld, Joop S E Laven.   

Abstract

CONTEXT: Polycystic ovary syndrome (PCOS) is associated with a higher frequency of cardiovascular risk factors. Apolipoprotein (apo) A-I and apoB are potent markers for cardiovascular risk. Data on apo levels in women with PCOS are scarce and contradictory.
OBJECTIVE: Our objective was to identify changes in lipid metabolism in women with PCOS, and the relative impact of obesity, insulin resistance, and hyperandrogenism on lipid parameters.
DESIGN: This was a case-control study.
SETTING: The study was performed at a single referral center.
SUBJECTS: PCOS was diagnosed according to the 2003 Rotterdam criteria. Healthy mothers with regular menstrual cycles served as controls. MAIN OUTCOME PARAMETERS: Fasting insulin, triglycerides (TGs), cholesterol, high-density lipoprotein (HDL)-cholesterol, apoA-I, and apoB were determined. Low-density lipoprotein (LDL)-cholesterol was calculated using the Friedewald formula.
RESULTS: We included 557 women with PCOS and 295 controls. After correction for age and body mass index, PCOS women had higher median levels of insulin (10.1 vs. 6.9 mU/liter), TGs (95 vs. 81 mg/dl), cholesterol (196 vs. 178 mg/dl), and LDL-cholesterol (125 vs. 106 mg/dl) in combination with lower levels of HDL-cholesterol (46 vs. 55 mg/dl) and apoA-I (118 vs. 146 mg/dl) compared with controls (all P values < or = 0.01). apoB levels were similar in cases and controls. Free androgen index, body mass index, SHBG, and estradiol were independent predictors of apoA-I levels in women with PCOS.
CONCLUSIONS: PCOS is associated with a more pronounced atherogenic lipid profile. Furthermore, obesity and hyperandrogenism contribute to an adverse lipid profile. Finally, PCOS seems to constitute an additional risk factor for an atherogenic lipid profile.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18056772     DOI: 10.1210/jc.2007-1756

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  38 in total

1.  Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women.

Authors:  Gordon I Smith; Jun Yoshino; Dominic N Reeds; David Bradley; Rachel E Burrows; Henry D Heisey; Anna C Moseley; Bettina Mittendorfer
Journal:  J Clin Endocrinol Metab       Date:  2013-12-20       Impact factor: 5.958

2.  Ovarian hypertension: polycystic ovary syndrome.

Authors:  Rhonda Bentley-Lewis; Ellen Seely; Andrea Dunaif
Journal:  Endocrinol Metab Clin North Am       Date:  2011-06       Impact factor: 4.741

Review 3.  Cardiometabolic Risk in PCOS: More than a Reproductive Disorder.

Authors:  Laura C Torchen
Journal:  Curr Diab Rep       Date:  2017-11-11       Impact factor: 4.810

Review 4.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 5.  Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.

Authors:  Mark O Goodarzi; Daniel A Dumesic; Gregorio Chazenbalk; Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

6.  Effect of metformin and flutamide on insulin, lipogenic and androgen-estrogen signaling, and cardiometabolic risk in a PCOS-prone metabolic syndrome rodent model.

Authors:  M Kupreeva; A Diane; R Lehner; R Watts; M Ghosh; S Proctor; D Vine
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-08-28       Impact factor: 4.310

7.  Cholesterol, endocrine and metabolic disturbances in sporadic anovulatory women with regular menstruation.

Authors:  Sunni L Mumford; Enrique F Schisterman; Anna Maria Siega-Riz; Audrey J Gaskins; Anne Z Steiner; Julie L Daniels; Andrew F Olshan; Mary L Hediger; Kathleen Hovey; Jean Wactawski-Wende; Maurizio Trevisan; Michael S Bloom
Journal:  Hum Reprod       Date:  2010-11-28       Impact factor: 6.918

Review 8.  Gender differences in cardiovascular disease: hormonal and biochemical influences.

Authors:  Faustino R Pérez-López; Luis Larrad-Mur; Amanda Kallen; Peter Chedraui; Hugh S Taylor
Journal:  Reprod Sci       Date:  2010-06       Impact factor: 3.060

9.  Effects of metformin plus rosuvastatin on hyperandrogenism in polycystic ovary syndrome patients with hyperlipidemia and impaired glucose tolerance.

Authors:  O Celik; O Acbay
Journal:  J Endocrinol Invest       Date:  2012-04-18       Impact factor: 4.256

10.  Cardiovascular disease markers in women with polycystic ovary syndrome with emphasis on asymmetric dimethylarginine and homocysteine.

Authors:  Ahmed M Mohamadin; Fawzia A Habib; Abdulrahman A Al-Saggaf
Journal:  Ann Saudi Med       Date:  2010 Jul-Aug       Impact factor: 1.526

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.